Biotech
Prime Medicine
Prime Medicine raises $315M Series B at $1.85B valuation
$315M
Total Raised
Series B
Latest Round
2019
Founded
250+
Employees
800 Boylston Street, Boston, MA 02199
1 min read
Quick Facts
Valuation
$1.85B
Latest Round Size
$315M
Latest Round Date
July 2024
Prime Medicine: Series B Funding Round
Prime Medicine has successfully raised $315M in Series B funding, reaching a valuation of $1.85B.
Company Overview
Prime editing gene therapy
Funding Details
The Series B round was led by GV, with participation from F-Prime Capital, Westlake Village BioPartners, ARCH Venture Partners, Deerfield Management.
Company Information
- Headquarters: 800 Boylston Street, Boston, MA 02199
- Founded: 2019
- Employees: 250+
- Category: Biotech
Investment
Prime Medicine plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- GV: Verified investor in Series B
- F-Prime Capital: Verified investor in Series B
- Westlake Village BioPartners: Verified investor in Series B
- ARCH Venture Partners: Verified investor in Series B
- Deerfield Management: Verified investor in Series B
Key Investors
GV
Lead Investor
Verified investor in Series B
F-Prime Capital
Investor
Verified investor in Series B
Westlake Village BioPartners
Investor
Verified investor in Series B
ARCH Venture Partners
Investor
Verified investor in Series B
Deerfield Management
Investor
Verified investor in Series B
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M